A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with major updates for antibody-drug conjugates, HER2-positive regimens, and ...

ASCO 2025 may be over, but the insights for the future of oncology are only just beginning. At the American Society of ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...